It’s been a very busy few months since the Enigma team took home the Disrupt Cup back in New York, and co-founder Hicham Oudghiri took the stage here in San Francisco today to deliver an update on the ...

ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment to start imminently; 12-week study results expected in Q4 2026 ...

The Independent Media Agencies of Australia (IMAA), the national industry body representing independent media agencies, has announced independent agency Enigma as the overall winner of its inaugural ...

There are “red lines,” a “window of opportunity,” the risk of a “zone of immunity,” and plenty of other cryptic terms about Iran’s nuclear program. What does it involve? Where is it leading? How and ...

This is an undesirable program. This file has been identified as a program that is undesirable to have running on your computer. This consists of programs that are misleading, harmful, or undesirable.

Milan, Italy, and Morristown, NJ, USA, August 12, 2025, 07:00 am CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of ...

The issuer is solely responsible for the content of this announcement. Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with ...